Are serum HBV RNA and HBeAg useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients?
Monitoring of serum HBV DNA + RNA levels may be a useful method for predicting re-activation of chronic hepatitis B after discontinuation of NA therapy.
FHL2 is a potent EMT inducer and might be an important mediator for invasion and/or metastasis of colon cancer.